Beer 2011 (3939. Beer TM, Bernstein GT, Corman JM, Glode LM, Hall SJ, Poll WL, et al. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Clin Cancer Res. 2011; 17: 4558-67.) |
Androgen-dependent prostate cancer |
Sanda 1999 (4040. Sanda MG, Smith DC, Charles LG, Hwang C, Pienta KJ, Schlom J, et al. Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology. 1999; 53: 260-6.) |
Not a randomized trial |
Madan 2009 (4141. Madan RA, Arlen PM, Mohebtash M, Hodge JW, Gulley JL. Prostvac-VF. a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs. 2009; 18: 1001-11.) |
Not a randomized trial |
Antonarakis 2010 (4242. Antonarakis ES, Drake CG. Current status of immunological therapies for prostate cancer. Curr Opin Urol. 2010; 20: 241-6.) |
Not a randomized trial |
Cha 2011 (4343. Cha E, Fong L. Immunotherapy for prostate cancer: biology and therapeutic approaches. J Clin Oncol. 2011; 29: 3677-85.) |
Not a randomized trial |
Joniau 2011 (4444. Joniau S, Abrahamsson PA, Bellmunt J, Figdor C, Hamdy F, Verhagen P, et al. Current vaccination strategies for prostate cancer. Eur Urol. 2012; 61: 290-306.) |
Not a randomized trial |
Madan 2010 (4545. Madan RA, Gulley JL. The current and emerging role of immunotherapy in prostate cancer. Clin Genitourin Cancer. 2010; 8: 10-6.) |
Not a randomized trial |
May 2011 (4646. May KF, Jr., Gulley JL, Drake CG, Dranoff G, Kantoff PW. Prostate cancer immunotherapy. Clin Cancer Res. 2011; 17: 5233-8.) |
Not a randomized trial |
Morse 2010 (4747. Morse MA, Whelan M. A year of successful cancer vaccines points to a path forward. Curr Opin Mol Ther. 2010; 12: 11-3.) |
Not a randomized trial |
McLeod 2011 (4848. McLeod DG, Quinn DI, Whitmore JB, Tabesh M, editors. Sipuleucel-T in African Americans: A subgroup analysis of three phase III sipuleucel-T trials in advanced prostate cancer. J Clin Oncol. 2011; 29: (Suppl; abstr e15148).) |
A subgroup analysis |
Fizazi 2011 (4949. Fizazi K, Powles T, George DJ, Poehlein CH, editors. A randomized, controlled phase III global trial comparing sipuleucel-T plus androgen deprivation therapy versus androgen deprivation therapy alone in men with metastatic androgen dependent (hormone sensitive) prostate cancer. J Clin Oncol. 2011; 29: (Suppl; abstr TPS188).) |
Androgen-dependent prostate cancer |
Beer 2011 (5050. Beer TM, Schellhammer PF, Corman JM, Glode LM, Hall S, Xu Y, et al.:, editors. Quality-of-life assessment in a randomized, double-blind study of sipuleucel-T in men with androgen-dependent prostate cancer. J Clin Oncol. 2011; 29: (Suppl; abstr 4648).) |
Androgen-dependent prostate cancer |
Penson 2006 (5151. Penson J, Holzbeierlein PA, Schellhammer MW, editors. Study results of active cellular immunotherapy with Sipuleucel-T in androgen independent prostate cancer suggest significant survival benefit with minimal toxicity. http://suonetorg/pdf/ProgramBooks/2006_SUO_ProgramBookpdf Poster #44. http://suonetorg/pdf/ProgramBooks/2006_S...
) |
Integrated analysis of studies analyzed (Small and Higano) |
Sonpavde 2011 (5252. Sonpavde G, Agarwal N, Choueiri TK, Kantoff PW. Recent advances in immunotherapy for the treatment of prostate cancer. Expert Opin Biol Ther. 2011; 11: 997-1009.) |
Not a randomized trial |
Beltran 2011 (11. Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, et al. New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol. 2011; 60: 279-90.) |
Not a randomized trial |
Drake 2010 (5353. Drake CG, Antonarakis ES. Update: immunological strategies for prostate cancer. Curr Urol Rep. 2010; 11: 202-7.) |
Not a randomized trial |
Cha 2010 (22. Cha E, Fong L. Therapeutic vaccines for prostate cancer. Curr Opin Mol Ther. 2010; 12: 77-85.) |
Not a randomized trial |
Harzstark 2009 (5454. Harzstark AL, Small EJ. Immunotherapeutics in development for prostate cancer. Oncologist. 2009; 14: 391-8.) |
Not a randomized trial |
Mohebtash 2008 (5555. Mohebtash M, Madan RA, Gulley JL, Arlen PM. Therapeutic prostate cancer vaccines: a review of the latest developments. Curr Opin Investig Drugs. 2008; 9: 1296-301.) |
Not a randomized trial |
Vaishampayan 2008 (5656. Vaishampayan U, Hussain M. Update in systemic therapy of prostate cancer: improvement in quality and duration of life. Expert Rev Anticancer Ther. 2008; 8: 269-81.) |
Not a randomized trial |
Harzstark 2008 (5757. Harzstark AL, Ryan CJ. Therapies in development for castrate-resistant prostate cancer. Expert Rev Anticancer Ther. 2008; 8: 259-68.) |
Not a randomized trial |
Barqawi 2007 (5858. Barqawi AB, Crawford ED. The current use and future trends of focal surgical therapy in the management of localized prostate cancer. Cancer J. 2007; 13: 313-7.) |
Not immunotherapy |
Arlen 2007 (5959. Arlen PM, Skarupa L, Pazdur M, Seetharam M, Tsang KY, Grosenbach DW, et al. Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol. 2007; 178(4 Pt 1):1515-20.) |
Not a randomized trial |
Di Lorenzo 2007 (6060. Di Lorenzo G, Autorino R, Figg WD, De Placido S. Hormone-refractory prostate cancer: where are we going? Drugs. 2007; 67: 1109-24.) |
Not a randomized trial |